Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0162871 (
abdominal aortic aneurysm
)
8,664
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A patient with mild
hypothyroidism
underwent a repair of
abdominal aortic aneurysm
. Although the serum TSH level of this patient was very high and T4, free T4 levels were low, T3 level remained within normal ranges. Inhalation anesthesia with continuous epidural block was selected and there was no complication such as hypotension or hypothermia during perioperative period. Recently, several reports demonstrate that the preoperative supplemental therapy of the thyroid hormone should not be necessary in the case of mild
hypothyroidism
. Moreover, the biological potency of T3 is higher than that of T4. Thus, in patients whose T3 level is kept within normal ranges even if serum T4 level is low and serum TSH level is high, we may say that they are in euthyroid state. We think these patients can be anesthetized safely.
...
PMID:[Anesthetic management of a patient with mild hypothyroidism]. 807 61
Patients with peripheral arterial disease (PAD) are at increased risk for all-cause mortality, cardiovascular mortality, and mortality from coronary artery disease. Smoking should be stopped and hypertension, dyslipidemia, diabetes mellitus, and
hypothyroidism
treated. Statins decrease the incidence of intermittent claudication and improve exercise duration until the onset of intermittent claudication in patients with PAD and hypercholesterolemia. The serum low-density lipoprotein cholesterol should be reduced to <70 mg/dL. Antiplatelet drugs such as aspirin or clopidogrel, angiotensin-converting enzyme (ACE) inhibitors, and statins should be given to patients with PAD. Beta blockers should be given if coronary artery disease is present. Cilostazol improves exercise time until intermittent claudication. Exercise rehabilitation programs should be used. Revascularization should be performed if indicated. Patients with an infrarenal or juxtarenal
abdominal aortic aneurysm
(
AAA
) measuring 5.5 cm or larger should undergo repair to eliminate the risk of rupture. Patients with an infrarenal or juxtarenal
AAA
measuring 4.0 to 5.4 cm in diameter should be monitored by ultrasound or computed tomographic scans every 6 to 12 months to detect expansion. Patients with an
AAA
should undergo intensive risk factor modification, be treated with ACE inhibitors, statins, and beta blockers, and undergo surgery if indicated.
...
PMID:Peripheral arterial disease and abdominal aortic aneurysm in elderly people. 2219 80
Ten articles published in 2012 and of interest for the practice of ambulatory general internal medicine are reviewed in this paper. Topics of public health issues, such as the association between sleep disorders and prediabetes, the association between prediabetes and stroke, and the harmful effects of prolonged sitting are tackled. Other focuses include hepatitis C screening,
abdominal aortic aneurysm
screening and prostatic cancer screening. Therapeutic aspects are reviewed, such as the management of nongonococcal urethritis, the treatment of iron deficiency without anemia and the substitution of subclinical
hypothyroidism
. Finally a new study about aspirin and cancer prevention is discussed.
...
PMID:[What is new in ambulatory internal medicine in 2012?]. 2341 47
Objective To clarify the underlying diseases, clinical manifestations, and treatment strategies for Amyloid A (AA) amyloidosis (
AAA
) in Japanese patients. Methods We conducted a survey on Japanese patients with
AAA
treated between January 1, 2012, and December 31, 2014. Results A total of 199 patients with
AAA
were included in the present study. The underlying diseases of
AAA
were rheumatoid arthritis (60.3%), uncharacterized inflammatory disorders (11.1%), neoplasms (7.0%), other rheumatic diseases (6.5%), inflammatory bowel diseases (4.5%), chronic infection (4.5%), Castleman's disease (4.0%), and autoinflammatory diseases (2.0%). The clinical manifestations at the diagnosis of
AAA
were moderate to severe renal dysfunction (46.2%), moderate to severe proteinuria (30.7%), intractable diarrhea (32.2%), melena (4.5%), paralytic ileus (3.5%), heart failure (11.6%), cardiac conduction disturbances (10.1%), arrhythmia (5.5%), and
hypothyroidism
(11.6%). Diagnostic biopsies were performed most frequently in the gastrointestinal tract (66.3%), followed by the kidneys (22.1%), heart (5.5%), abdominal fat (4.0%), and others (3.0%). Biologics were used to treat 97 patients with
AAA
(48.7%). Tocilizumab (TCZ) was administered to 66 patients, with 95.5% showing good responses. Anti-TNF agents were administered to 27 patients, with 74.1% showing good responses. The treatment effects of TCZ were significantly superior to those of anti-TNF agents (p<0.007). Conclusion The most common underlying diseases of
AAA
were rheumatic diseases. Uncharacterized inflammatory disorders and neoplasms were also frequently observed in patients with
AAA
. Renal and gastrointestinal manifestations were common and important for the diagnosis of
AAA
, with cardiac manifestations also being of significance. Biologics, particularly TCZ, were effective therapeutic modalities.
...
PMID:First Nationwide Survey of 199 Patients with Amyloid A Amyloidosis in Japan. 3010 21